S. David Miller

1.0k total citations
23 papers, 666 citations indexed

About

S. David Miller is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Immunology and Allergy. According to data from OpenAlex, S. David Miller has authored 23 papers receiving a total of 666 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Physiology, 13 papers in Pulmonary and Respiratory Medicine and 9 papers in Immunology and Allergy. Recurrent topics in S. David Miller's work include Asthma and respiratory diseases (16 papers), Allergic Rhinitis and Sensitization (9 papers) and Inhalation and Respiratory Drug Delivery (8 papers). S. David Miller is often cited by papers focused on Asthma and respiratory diseases (16 papers), Allergic Rhinitis and Sensitization (9 papers) and Inhalation and Respiratory Drug Delivery (8 papers). S. David Miller collaborates with scholars based in United States, United Kingdom and Switzerland. S. David Miller's co-authors include K. B. Nolop, David S. Pearlman, Alan A. Wanderer, J. A. Alonso, C. V. Damaraju, James P. Rosen, Edwin A. Bronsky, Zachary M. Pine, Eric Schenkel and Anthony R. Rooklin and has published in prestigious journals such as PEDIATRICS, CHEST Journal and Journal of Allergy and Clinical Immunology.

In The Last Decade

S. David Miller

22 papers receiving 625 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. David Miller United States 12 439 299 225 101 81 23 666
Francesca Occasi Italy 17 258 0.6× 129 0.4× 134 0.6× 94 0.9× 25 0.3× 24 511
D. Gatland United Kingdom 12 179 0.4× 142 0.5× 83 0.4× 157 1.6× 14 0.2× 24 486
Alper Yenigün Türkiye 15 130 0.3× 62 0.2× 79 0.4× 293 2.9× 19 0.2× 102 637
Muhammad Shakeel United Kingdom 13 80 0.2× 55 0.2× 91 0.4× 202 2.0× 27 0.3× 67 417
Sameh M. Ragab Egypt 16 336 0.8× 341 1.1× 141 0.6× 471 4.7× 9 0.1× 27 891
Nikita Chapurin United States 13 63 0.1× 95 0.3× 61 0.3× 177 1.8× 14 0.2× 37 493
Evren Erkul Türkiye 15 91 0.2× 25 0.1× 91 0.4× 263 2.6× 26 0.3× 45 503
Öner Sakallıoğlu Türkiye 11 100 0.2× 23 0.1× 38 0.2× 152 1.5× 19 0.2× 44 349
G Santangelo Italy 12 279 0.6× 17 0.1× 229 1.0× 60 0.6× 89 1.1× 51 546
J. Alberty Germany 12 70 0.2× 26 0.1× 117 0.5× 147 1.5× 18 0.2× 38 365

Countries citing papers authored by S. David Miller

Since Specialization
Citations

This map shows the geographic impact of S. David Miller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. David Miller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. David Miller more than expected).

Fields of papers citing papers by S. David Miller

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. David Miller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. David Miller. The network helps show where S. David Miller may publish in the future.

Co-authorship network of co-authors of S. David Miller

This figure shows the co-authorship network connecting the top 25 collaborators of S. David Miller. A scholar is included among the top collaborators of S. David Miller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. David Miller. S. David Miller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ng, Dik, Edward Kerwin, Martha V. White, et al.. (2019). Clinical Bioequivalence of Wixela Inhub and Advair Diskus in Adults With Asthma. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 33(2). 99–107. 11 indexed citations
2.
Allan, Richard, et al.. (2019). Pulmonary Therapeutic Bioequivalence of Wixela® Inhub® and Advair® Diskus® in Adults with Asthma. A2205–A2205. 1 indexed citations
3.
Miller, S. David, et al.. (2018). Randomized dose-ranging study of a budesonide metered-dose inhaler by using co-suspension delivery technology in asthma. Allergy and Asthma Proceedings. 39(5). 350–358.
4.
Viirre, Erik, J. Ernest Villafranca, S. David Miller, Paul J Gomes, & Elliott C. Lasser. (2016). Contrast Agent Reduces Allergic Rhinitis Symptoms. Journal of Allergy and Clinical Immunology. 137(2). AB262–AB262. 2 indexed citations
5.
Erpenbeck, Veit J., Todor A. Popov, S. David Miller, et al.. (2015). QAW039 (fevipiprant) improves lung function and control of asthma symptoms in patients with more severe air flow limitation: A proof-of-concept study. PA2125–PA2125. 5 indexed citations
6.
7.
Kosoglou, Teddy, James Hubbell, David L. Cutler, et al.. (2013). Hypothalamic-Pituitary-Adrenal Axis Effects of Mometasone Furoate/Formoterol Fumarate vs Fluticasone Propionate/Salmeterol Administered Through Metered-Dose Inhaler. CHEST Journal. 144(6). 1795–1802. 4 indexed citations
8.
LaForce, Craig, et al.. (2013). Ocular safety of fluticasone furoate nasal spray in patients with perennial allergic rhinitis: a 2-year study. Annals of Allergy Asthma & Immunology. 111(1). 45–50. 22 indexed citations
9.
Miller, S. David. (2012). The acute and preventative treatment of episodic migraine. Annals of Indian Academy of Neurology. 15(5). 33–33. 15 indexed citations
10.
Ratner, Paul H., et al.. (2012). Once-daily treatment with beclomethasone dipropionate nasal aerosol does not affect hypothalamic-pituitary-adrenal axis function. Annals of Allergy Asthma & Immunology. 109(5). 336–341. 14 indexed citations
11.
Miller, S. David, et al.. (2012). 932. Critical Care Medicine. 40. 1–328. 1 indexed citations
12.
13.
Miller, S. David, Saif Razvi, & Aline Russell. (2010). Reading epilepsy. Practical Neurology. 10(5). 278–281. 11 indexed citations
14.
Shrewsbury, Stephen B., Shashidhar Kori, S. David Miller, Andrew Pedinoff, & Steven F. Weinstein. (2008). Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics. Current Medical Research and Opinion. 24(7). 1977–1985. 23 indexed citations
15.
Kemp, James P., Robert Berkowitz, S. David Miller, et al.. (2000). Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma. Journal of Allergy and Clinical Immunology. 106(3). 485–492. 70 indexed citations
16.
Schenkel, Eric, David P. Skoner, Edwin A. Bronsky, et al.. (2000). Absence of Growth Retardation in Children With Perennial Allergic Rhinitis After One Year of Treatment With Mometasone Furoate Aqueous Nasal Spray. PEDIATRICS. 105(2). e22–e22. 248 indexed citations
17.
Miller, S. David, et al.. (1994). Follow-Up of Hymenoptera-Sensitive Patients Without Active Immunotherapy. Allergy and Asthma Proceedings. 15(2). 65–68. 3 indexed citations
18.
Miller, S. David, et al.. (1993). TRANSVERSE MYELITIS COMPLICATING SYSTEMIC LUPUS ERYTHEMATOSUS: TREATMENT INCLUDING HYDROXYCHLOROQUINE. American Journal of Physical Medicine & Rehabilitation. 72(3). 158–161. 19 indexed citations
19.
Miller, S. David, et al.. (1992). Delayed Nasal Mucociliary Clearance in Patients with Nonallergic Rhinitis and Nasal Eosinophilia. Allergy and Asthma Proceedings. 13(2). 81–84. 10 indexed citations
20.
Pine, Zachary M., S. David Miller, & J. A. Alonso. (1991). ATRIAL FIBRILLATION ASSOCIATED WITH AUTONOMIC DYSREFLEXIA. American Journal of Physical Medicine & Rehabilitation. 70(5). 271–273. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Francesca Occasi Breakdown of academic impact, for papers by D. Gatland Breakdown of academic impact, for papers by Alper Yenigün Breakdown of academic impact, for papers by Muhammad Shakeel Breakdown of academic impact, for papers by Sameh M. Ragab Breakdown of academic impact, for papers by Nikita Chapurin Breakdown of academic impact, for papers by Evren Erkul Breakdown of academic impact, for papers by Öner Sakallıoğlu Breakdown of academic impact, for papers by G Santangelo Breakdown of academic impact, for papers by J. Alberty
Rankless by CCL
2026